This section has no associated Explanatory Memorandum
175. For regulation 216 (amendment of Schedule 30 (particulars for advertisements to persons qualified to prescribe or supply)) substitute—U.K.
“216. In Schedule 30—
(a)in paragraphs 1, 2 and 6, for “marketing authorisation,” substitute “ UK marketing authorisation, EU marketing authorisation ”;
(b)after paragraph 2 insert—
“2A. In relation to an advertisement in Great Britain (other than an advertisement falling within the exception in regulation 296) where the medicinal product concerned is authorised under a UKMA(GB), a statement that the product concerned is authorised under a UKMA(GB).”.”.
Commencement Information
I1Sch. 2 para. 175 in force at 31.12.2020 immediately before IP completion day, see reg. 1